Autoimmune Diseases  >>  GSK 2018682  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GSK 2018682 / GSK
NCT01387217: GSK2018682 FTIH in Healthy Volunteers

Completed
1
27
RoW
GSK2018682, Placebo
GlaxoSmithKline
Multiple Sclerosis
12/10
12/10
NCT01466322: A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.

Completed
1
16
RoW
GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
02/11
02/11
NCT01431937: Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers

Completed
1
40
RoW
GSK2018682, Placebo
GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
03/11
03/11

Download Options